Education
About Us
Working with TipRanks
Follow Us
BIOLASE (BIOLQ)
OTHER OTC:BIOLQ
Top Page
BIOLASE
(OTC:BIOLQ)
Select Model
Select Model
Rating:32Underperform
Price Target:―
BIOLASE's overall stock score reflects significant financial and operational challenges, with persistent losses and cash flow issues being primary concerns. Weak technical indicators and poor valuation metrics further weigh on the stock's attractiveness. The lack of positive earnings guidance or corporate events leaves the outlook uncertain, resulting in a low overall stock score.
BIOLASE (BIOLQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.66K
Dividend YieldN/A
Average Volume (3M)69.31K
Price to Earnings (P/E)―
Beta (1Y)86.14
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,597,336
10 Day Avg. Volume87,374
30 Day Avg. Volume69,307
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.49K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BIOLASE Business Overview & Revenue Model
Company DescriptionBIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
How the Company Makes MoneyBIOLASE generates revenue primarily through the sale of its dental laser systems and related accessories. The company offers a variety of laser products tailored to different dental needs, which are sold directly to dental professionals and through distributors. Additionally, BIOLASE earns money from providing training and support services to its customers, ensuring they can effectively utilize the laser systems. The company may also engage in strategic partnerships and collaborations with other dental industry firms to enhance its offerings and expand market reach, contributing to its revenue streams.
BIOLASE Earnings Call Summary
Earnings Call Date:May 13, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook with notable achievements in market penetration and cost reduction, despite some challenges in the economic environment and slow technology adoption. The company remains optimistic about achieving its growth and profitability targets.Q1-2024 Updates
Positive Updates
Increased Adoption of Laser Technology
67% of U.S. Waterlase sales were from new customers, with 42% from dental specialists, indicating growing market penetration.
Strong Consumable Sales Growth
Consumable sales experienced a 14% year-over-year increase, marking the third strongest quarter for consumables in company history.
Reduction in Adjusted EBITDA Loss
Adjusted EBITDA loss decreased by 21% compared to the same quarter last year, indicating improved operational efficiency.
Cost Reduction Initiatives Success
Operating expenses decreased by 9%, largely due to cost-saving measures including a 20% reduction in workforce.
Positive Growth Outlook
Reiterated full-year 2024 guidance with expected revenue growth of 6%-8% year-over-year, aiming for positive adjusted EBITDA.
Negative Updates
Challenging Economic Environment
Elevated interest rates continue to impact sales, though the company remains optimistic about future growth.
Flat Gross Margin
Gross margin remained relatively flat compared to the previous year, though there is an expectation of improvement as cost-saving measures take effect.
Slow Market Adoption
While efforts are being made to increase adoption, the dental community remains slow in adopting new technologies.
Company Guidance
During the BIOLASE Q1 2024 earnings call, executives provided detailed guidance and performance metrics, highlighting a strong quarter for the company. John Beaver, President and CEO, underscored the growing adoption of their laser technology, noting that 67% of U.S. Waterlase sales were to new customers, with 42% attributed to dental specialists, amidst a significant untapped market where over 90% of dentists have yet to adopt all-tissue laser technology. The company maintained a 60% global market share and saw consumable sales increase by 14% year-over-year, marking the third strongest quarter for consumable sales. Operational improvements led to a 21% reduction in adjusted EBITDA loss, and cost-saving strategies yielded a 9% decrease in operating expenses. CFO Jennifer Bright reaffirmed full-year guidance with expected revenue growth of 6% to 8%, targeting $52 million to $53 million, and projected achieving positive adjusted EBITDA for the year, driven by cost reductions, price increases, and enhanced operational efficiency.BIOLASE Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
35
Negative
Cash Flow
30
Negative
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 16.72M | 15.91M | 16.53M | 6.17M | 14.29M |
| EBITDA | -15.02M | -25.28M | -12.32M | -13.84M | -16.59M |
| Net Income | -20.63M | -28.63M | -15.53M | -16.83M | -17.86M |
Balance Sheet | |||||
| Total Assets | 35.10M | 38.19M | 55.25M | 41.02M | 31.85M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 14.82M | 15.05M | 15.05M | 17.96M | 13.47M |
| Total Liabilities | 33.15M | 33.30M | 30.08M | 31.00M | 27.50M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -15.23M | -30.49M | -17.42M | -12.89M | -12.95M |
| Operating Cash Flow | -14.10M | -26.76M | -16.71M | -12.79M | -12.75M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
BIOLASE Technical Analysis
Negative
0.01
Price Trends
<0.01
Positive
0.02
Negative
0.17
Negative
Market Momentum
>-0.01
Negative
38.89
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOLQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, above the 50-day MA of <0.01, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.89 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOLQ.
BIOLASE Risk Analysis
BIOLASE disclosed 7 risk factors in its most recent earnings report. BIOLASE reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BIOLASE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $3.92M | -0.04 | -1371.21% | ― | -13.90% | 44.89% | |
34 Underperform | $7.49M | -0.16 | -189.72% | ― | ― | 70.57% | |
32 Underperform | $3.66K | >-0.01 | ― | ― | ― | ― | |
29 Underperform | $2.85M | -0.05 | -126.20% | ― | ― | 97.70% | |
24 Underperform | $2.95M | -0.04 | -261.96% | ― | ― | 80.53% | |
15 Underperform | $2.09M | -0.08 | -231.27% | ― | ― | 85.78% |
* Healthcare Sector Average
BIOLQ
BIOLASE
0.01
0.00
0.00%
VERO
Venus Concept
1.87
-1.82
-49.32%
ENVB
Enveric Biosciences
5.98
-67.41
-91.85%
INAB
IN8bio
1.70
-7.80
-82.11%
DRMA
Dermata Therapeutics
3.12
-9.18
-74.63%
BJDX
Bluejay Diagnostics
1.62
-3.58
-68.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.